Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

It’s an approach that has already yielded one FDA- and EMA-approved product – Amgen’s Imlygic (talimogene laherparepvec) – which was launched in 2015 for melanoma but hasn’t made much

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....